FRACTYL HEALTH INC (GUTS) Stock Price, Quote, News and Overview
NASDAQ:GUTS - Nasdaq - US35168W1036 - Common Stock - Currency: USD
GUTS Quote, Performance and Key Statistics
NASDAQ:GUTS (8/7/2025, 4:00:00 PM)
0.9727
-0.04 (-3.69%)
The current stock price of GUTS is 0.9727 USD. In the past month the price decreased by -33.99%. In the past year, price decreased by -43.26%.
GUTS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.95 | 229.76B | ||
| ISRG | INTUITIVE SURGICAL INC | 58.36 | 168.42B | ||
| BSX | BOSTON SCIENTIFIC CORP | 36.38 | 152.32B | ||
| SYK | STRYKER CORP | 29.29 | 143.83B | ||
| MDT | MEDTRONIC PLC | 16.59 | 116.90B | ||
| BDX | BECTON DICKINSON AND CO | 13.32 | 53.79B | ||
| IDXX | IDEXX LABORATORIES INC | 54.13 | 52.28B | ||
| EW | EDWARDS LIFESCIENCES CORP | 30.32 | 45.71B | ||
| RMD | RESMED INC | 29.34 | 41.08B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.26 | 32.56B | ||
| DXCM | DEXCOM INC | 44.94 | 29.96B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 15.93 | 25.62B |
Related stock screener links
About GUTS
Company Profile
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Company Info
FRACTYL HEALTH INC
3 Van De Graaff Drive, Suite 200
Burlington MASSACHUSETTS US
Employees: 112
Phone: 17819028800
FRACTYL HEALTH INC / GUTS FAQ
What is the stock price of FRACTYL HEALTH INC today?
The current stock price of GUTS is 0.9727 USD. The price decreased by -3.69% in the last trading session.
What is the ticker symbol for FRACTYL HEALTH INC stock?
The exchange symbol of FRACTYL HEALTH INC is GUTS and it is listed on the Nasdaq exchange.
On which exchange is GUTS stock listed?
GUTS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FRACTYL HEALTH INC stock?
9 analysts have analysed GUTS and the average price target is 9.52 USD. This implies a price increase of 878.72% is expected in the next year compared to the current price of 0.9727. Check the FRACTYL HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FRACTYL HEALTH INC worth?
FRACTYL HEALTH INC (GUTS) has a market capitalization of 47.64M USD. This makes GUTS a Nano Cap stock.
How many employees does FRACTYL HEALTH INC have?
FRACTYL HEALTH INC (GUTS) currently has 112 employees.
What are the support and resistance levels for FRACTYL HEALTH INC (GUTS) stock?
FRACTYL HEALTH INC (GUTS) has a resistance level at 1.99. Check the full technical report for a detailed analysis of GUTS support and resistance levels.
Is FRACTYL HEALTH INC (GUTS) expected to grow?
The Revenue of FRACTYL HEALTH INC (GUTS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the GUTS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FRACTYL HEALTH INC (GUTS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GUTS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GUTS, evaluating the profitability, health, valuation and growth aspects
- FRACTYL HEALTH INC (GUTS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FRACTYL HEALTH INC (GUTS) Sales and EPS estimates to see what analysts future expectations are.
- FRACTYL HEALTH INC (GUTS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FRACTYL HEALTH INC (GUTS) Insider and Institutional Ownership to learn about the owners and their transactions.
- FRACTYL HEALTH INC (GUTS) Stock Chart to make your own analysis
- FRACTYL HEALTH INC (GUTS) Latest news and press-releases to stay up to date.
Does FRACTYL HEALTH INC (GUTS) stock pay dividends?
GUTS does not pay a dividend.
When does FRACTYL HEALTH INC (GUTS) report earnings?
FRACTYL HEALTH INC (GUTS) will report earnings on 2025-08-13.
What is the Price/Earnings (PE) ratio of FRACTYL HEALTH INC (GUTS)?
FRACTYL HEALTH INC (GUTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.85).
What is the Short Interest ratio of FRACTYL HEALTH INC (GUTS) stock?
The outstanding short interest for FRACTYL HEALTH INC (GUTS) is 4.06% of its float. Check the ownership tab for more information on the GUTS short interest.
GUTS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GUTS. When comparing the yearly performance of all stocks, GUTS is a bad performer in the overall market: 95.77% of all stocks are doing better.
GUTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GUTS. GUTS may be in some trouble as it scores bad on both profitability and health.
GUTS Financial Highlights
Over the last trailing twelve months GUTS reported a non-GAAP Earnings per Share(EPS) of -1.85. The EPS increased by 11.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -107.31% | ||
| ROE | -1397.65% | ||
| Debt/Equity | 4.61 |
GUTS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to GUTS. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -2% and a revenue growth -100% for GUTS